AUSTIN, Texas, Aug. 3 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. announced today that it will deliver a presentation at the 26th Annual Canaccord Adams Summer Seminar in Boston. Dr. Robert E. Sobol, Introgen’s senior vice president of Medical and Scientific Affairs, is scheduled to present to leading institutional investment representatives on Tuesday, August 8, 2006, at the Boston Marriott Long Wharf Hotel.
Dr. Sobol will join executives from nearly 200 public and private companies for the Summer Seminar, one of the longest-running institutional events focused exclusively on growth companies. Introgen’s presentation will be web cast live and can be accessed at: http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=INGN&item_id=13
Also participating at the conference is Max W. Talbott, Introgen’s senior vice president of Worldwide Commercial Development. Dr. Talbott will participate in a panel discussion about Accelerated Approvals for Oncology Drugs. The panel will be held on Tuesday, August 8 from 12:00 -12:55 p.m. ET.
“We look forward to showcasing our company to some of the country’s top growth investors at this year’s Summer Seminar,” said David G. Nance, President and CEO of Introgen. “This is an ideal venue in which we can provide an important mid-year update of our growth strategy and achievements.”
“This year’s conference marks an important occasion since our new global platform allows us to substantially expand the scope of the event,” said Kevin Dunn, President and CEO of Canaccord Adams Inc. “The Summer Seminar strives to be a top-quality event for institutional clients and venture capitalists, connecting them with excellent growth industries while also giving corporate clients access to investing insights and valuable information. Our goal is providing a premier forum for information flow and networking for public and private growth companies, venture capitalists and institutional investors.”
The Canaccord Adams Annual Summer Seminar is one of the oldest and largest programs showcasing both publicly traded and privately held growth companies. Most of the presenting public companies are covered by Canaccord Adams’ global team of equity analysts. To learn more about the conference, please contact Nadine Miller at 617.371.3842 or Nadine.Miller@CanaccordAdams.com .
Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutics, immunotherapies, vaccines and nano-particle therapies to treat a wide range of cancers using tumor suppressors and cytokines. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility.
Canaccord Adams is a leading independent financial services firm committed to fostering the entrepreneurial economy by bringing corporate and institutional clients unique perspective on global investment opportunities. With operations in research, sales and trading, and investment banking, our 225 professionals seek out emerging opportunities in our key sectors - Mining and Metals, Energy, Technology, Life Sciences, Real Estate and Gaming, Consumer and Industrial Growth. Located in nine offices internationally, our experienced team generates focused, actionable ideas that identify opportunity and facilitate growth. More information is available at http://www.canaccordadams.com . Canaccord Adams Inc., Member NASD/SIPC.
Statements in this release that are not strictly historical may be “forward-looking” statements, including those relating to Introgen’s future success with its clinical development program for treatment of cancer and other diseases. The actual results may differ from those described in this release due to risks and uncertainties that exist in Introgen’s operations and business environment, including Introgen’s stage of product development and the limited experience in the development of gene-based drugs in general, dependence upon proprietary technology and the current competitive environment, history of operating losses and accumulated deficits, reliance on collaborative relationships, and uncertainties related to clinical trials, the safety and efficacy of Introgen’s product candidates, the ability to obtain the appropriate regulatory approvals, Introgen’s patent protection and market acceptance, as well as other risks detailed from time to time in Introgen’s filings with the Securities and Exchange Commission including its filings on Form 10-K and Form 10-Q. Introgen undertakes no obligation to publicly release the results of any revisions to any forward-looking statements that reflect events or circumstances arising after the date hereof.
Editor’s Note: For more information on Introgen Therapeutics, or for a menu of archived press releases, please visit Introgen’s Website at: http://www.introgen.com .
Contact: Introgen Therapeutics, Inc. C. Channing Burke (512) 708 9310 Ext. 322 Email: c.burke@introgen.com
Introgen Therapeutics, Inc.
CONTACT: C. Channing Burke of Introgen Therapeutics, Inc.,+1-512-708-9310, ext. 322, c.burke@introgen.com
